REGENXBIO Inc.

$80$125

REGENXBIO Inc is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Company’s gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies which intended to impact disease. Company is engaged in developing and offering gene therapy product candidates which use adeno-associated virus (AAV) vectors from our proprietary gene delivery platform, which is called NAV Technology Platform

Report ID:

UMHE21210

Published:

Jan-2022

Pages:

13

Industry:

HeadQuatered Country:

United States

Geography:

Clear
  Get a Free Sample
SKU: UMHE21210 Category:
Scope
Table of content
Companies Mentioned

Scope

“Overview of the company and its product offering
Detailed insight into its Strategy, Value, Product Portfolio, and Business Headquarter
Information on its recent developments including collaborations, and expansions among others
Biography of top management”

You can also purchase parts of this report. Do you want to check out a section wise
price list?

“1.    Key Facts of the Company
2.    Company Mission
3.    Growth Strategy
4.    Key Products & Services Offered
5.    Company Timeline
6.    Executive Team
7.    SWOT Analysis
8.    Key Financials
9. Recent Developments
9.1 Product Launches
9.2 Partnerships, Business Expansions & Investments “

Companies Mentioned

“Pfizer Inc.
Ultragenyx Pharmaceutical Inc.”